Business Wire

ARBORXR

25.5.2022 19:39:05 CEST | Business Wire | Press release

Share
ArborXR Announces Strategic Collaboration with Qualcomm Technologies, Helping Companies Scale VR and AR Deployments

ArborXR announced today the company will work with Qualcomm Technologies, Inc. on an extended reality (XR) mobile device management (MDM) platform to make it easier for companies to scale virtual reality (VR) and augmented (AR) headset deployments.

By working closely with original equipment manufacturer (OEM) partners and direct enterprise clients, ArborXR and Qualcomm Technologies have identified key problems that still exist in scaling a fleet of XR headsets. Companies today looking to deploy a fleet of VR or AR devices face many challenges enrolling and provisioning headsets, managing them remotely, installing apps and updates, and controlling the user experience.

To solve these problems, ArborXR will provide device management software to Qualcomm Technologies’ XR customers and OEMs with large-scale deployments for use with Qualcomm Technologies’ cutting edge VR/AR hardware available. OEMs will be able to pre-install ArborXR, and ArborXR’s software will support new VR and AR reference designs from Qualcomm Technologies early in the development cycle.

ArborXR’s software allows organizations to manage VR & AR devices, deploy apps remotely, and lock down the user experience with a kiosk mode and a customizable launcher. Current ArborXR customers include Fortune 500 companies, universities and hundreds of independent software vendors.

“With large scale deployments, we’ve increasingly seen a need for this kind of deeper integration,” said ArborXR CEO Brad Scoggin. “By working with Qualcomm Technologies at the Snapdragon® platform level and directly with OEMs, we will be able to provide companies a powerful and seamless platform for managing their fleets.”

“We recognize the friction that still exists in deploying large numbers of VR & AR devices. Working with ArborXR can help us solve this problem,” said Said Bakadir, senior director of XR product management, Qualcomm Technologies, Inc. “We are confident this collaboration with ArborXR will result in tremendous benefits for our customers and partners as we support their efforts to manage large-scale deployments.”

Companies can get started using ArborXR for free on up to 50 devices. To learn more, visit ArborXR.com .

About ArborXR

ArborXR puts you in command of XR device management. Confidently manage VR & AR devices at scale, remotely deploy content, and control what users can see and do. ArborXR is built with enterprise-level security and through working closely with dozens of Fortune 500 companies. Our mission is to help people live more meaningful lives through the power of XR. Join more than 600 companies in 60 countries already using ArborXR to manage their AR and VR fleets and learn more at ArborXR.com .

Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries. Snapdragon is a trademark or registered trademark of Qualcomm Incorporated.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Novatus Global Receives a King’s Award for Enterprise6.5.2026 08:00:00 CEST | Press release

Novatus Global Limited (“Novatus” “Novatus Global” or “the Company”), an award-winning provider of regulatory technology solutions and consulting services to global financial institutions, has been honoured with a King’s Award for Enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505378016/en/ Novatus is one of only 185 organisations nationally to be recognised with a prestigious King’s Award for Enterprise in 2026. Announced today (Wednesday 6 May), the Award acknowledges the company’s outstanding achievement in Innovation. Novatus Global, founded in 2019, employs over 100 people across London, the U.S., Australia, and India and has rapidly established itself as a trusted partner to many of the world’s leading banks, asset managers, and financial institutions. Its flagship product, Novatus En:ACT, is a market-leading SaaS platform delivering complete, real-time assurance across global transaction reporting regim

Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 05:00:00 CEST | Press release

NIQ insights drive international expansion and measurable growth for Hisense across key global markets NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth need

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release

Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release

Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s

IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release

Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye